Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021–2023

Locoregional Failure During and After Short-course Radiotherapy followed by Chemotherapy and Surgery Compared to Long-course Chemoradiotherapy and Surgery – A Five-year Follow-up of the RAPIDO Trial

(2023) Esmée A. Dijkstra et al.   ANNALS OF SURGERY

NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).

(2023) Laura A. Dawson et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial

(2023) Renu R. Bahadoer et al.   EUROPEAN JOURNAL OF CANCER

A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance–Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer

(2023) Parag Jitendra Parikh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)

(2023) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Treatment of Locally Advanced Rectal Cancer

(2023) Deborah Schrag et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

(2022) Howard P Safran et al.   LANCET ONCOLOGY

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

(2022) Yujin Xu et al.   CLINICAL CANCER RESEARCH

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

(2022) Julio Garcia-Aguilar et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

(2022) Rainer Fietkau et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

(2021) Thierry Conroy et al.   LANCET ONCOLOGY

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

(2021) Ronan J. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)

(2021) Maarten C. C. M. Hulshof et al.   JOURNAL OF CLINICAL ONCOLOGY

Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26)

(2021) G. Crehange et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial

(2020) Maxime J.M. van der Valk et al.   RADIOTHERAPY AND ONCOLOGY

Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study

(2020) Laura M Fernandez et al.   LANCET ONCOLOGY

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

(2020) Renu R Bahadoer et al.   LANCET ONCOLOGY

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Organ Preservation in Rectal Cancer: The Patients' Perspective

(2019) Cihan Gani et al.   Frontiers in Oncology

Network meta-analysis of protocol-driven care and laparoscopic surgery for colorectal cancer

(2016) A. C. Currie et al.   BRITISH JOURNAL OF SURGERY

The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus

(2016) D. Sebag-Montefiore et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

(2016) Pascal Hammel et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial

(2015) Julio Garcia-Aguilar et al.   LANCET ONCOLOGY

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control

(2014) R. Glynne-Jones et al.   ANNALS OF ONCOLOGY

Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

(2014) A. J. Breugom et al.   ANNALS OF ONCOLOGY

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

(2012) P. van Hagen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET